The Mark Foundation for Cancer Research is a non-profit organization dedicated to accelerating research that will transform the prevention, diagnosis, and treatment of cancer. The foundation supports innovative science that is not yet eligible for significant funding from large agencies, aiming to propel high-impact discoveries towards clinical application.

The Mark Foundation for Cancer Research

The Mark Foundation for Cancer Research actively partners with scientists to accelerate research that will transform the prevention, diagnosis, and treatment of cancer. We fulfill our mission by supporting groundbreaking science carried out by individual investigators, multi-disciplinary teams, and inter-institutional collaborations in the United States and across the globe. Recognizing the obstacles that prevent scientific advances from improving patient outcomes, we maintain a nimble, high-impact approach to funding research through grants for basic and translational cancer research and venture investments in early-stage companies that bridge the gap between bench and bedside.

On #WorldCancerResearchDay, we join the global cancer community in celebrating the lifesaving work done by cancer researchers worldwide, and we thank our Mark Foundation grantees at over 100 academic institutions across 13 countries for their trailblazing work. #cancerresearch

We are thrilled to share the news of Mark Foundation portfolio company Hyku Biosciences coming out of stealth. Congrats to the Hyku team on launching with $56M to advance its covalent medicines platform. Special shout out to Mark Foundation Emerging Leader Awardee Ken Hsu, Hyku scientific founder. #biotech #cancerresearch

With a $1.7 million Mark Foundation Drug Discovery Award, Perlmutter Cancer Center investigator Alec Kimmelman, MD, PhD, together with Seth Parker, PhD, at the The University of British Columbia, are seeking to identify a treatment for pancreatic ductal adenocarcinoma (PDAC), one of the deadliest forms of cancer. Read more here in NYU Langone Health's "Physician Focus":

Happy to share our latest roundup of news in The Mark Foundation News & Notes featuring updates from the past six months of work we’ve funded, events, the many accomplishments of our grantees, and more. Read our newsletter here: https://bit.ly/441LdJT

Promising preclinical data rolling out from our portfolio company Interius BioTherapeutics founded by Mark Foundation Emerging Leader Awardee Saar Gill. Congrats to the team on moving closer to realizing the transformational promise of in vivo CAR-T cell therapy.

The Mark Foundation is honored to welcome Nicola Mendelsohn CBE, Head of Global Business Group at Meta, and Professor Dr. Otmar Wiestler, President of Germany’s Helmholtz-Gemeinschaft / Helmholtz Association, to our Board of Directors! Read more:

Congratulations to Christian Hofmann, PhD, on being appointed CEO of Vicinitas Therapeutics, part of The Mark Foundation’s venture investment portfolio!

The Mark Foundation is proud to be a Cancer Grand Challenges partner and funder of the SPECIFICANCER and NexTGen teams. Read about our CEO Ryan Schoenfeld's perspective on these critical research projects published in the annual progress magazine Discover https://bit.ly/3nmlJqD #cancerresearch

The Mark Foundation team, including Ryan Schoenfeld, Ray DuBois, and Becky Bish, are at #AACR23 to hear the latest in cancer research and to catch up with our grantees and advisors. The impact of the research we fund has been on full display, with eight Major Symposia chaired by investigators with Mark Foundation grants – including three of our Emerging Leader Awardees, which is an outstanding recognition of the work of these early-career investigators. Note: LOIs for the 2024 Emerging Leader Award are being accepted through 5/1 at https://bit.ly/3Iw678s

Mark Foundation grantees work relentlessly to accelerate innovative cancer research. Check out the latest roundup of their high-profile publications from the past quarter here:

Metric
Company Name	The Mark Foundation for Cancer Research
Symbol
MSH ID	ORG:THEMARKFOUNDATION
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Healthcare Research
Country	US
Stage
Employee Count	15
Website	themarkfoundation.org
LinkedIn	themarkfoundation
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ORG:THEMARKFOUNDATION

The Mark Foundation for Cancer Research

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue